Tag: insulin access

Sanofi to Slash Price of Lantus by 78%, Cap Out-of-Pocket Costs to $35

Sanofi has capped monthly out-of-pocket costs for Lantus to $35 for all with commercial insurance and will cut the price of Lantus by 78%, effective January 1, 2024.

$25 List Price + $35 Copay Caps: Lilly’s New Insulin Cost Reductions

On March 1, 2023, insulin manufacturer Lilly announced expanded insulin cost-saving measures for people with and without health insurance coverage.

Congress Wants You to Know About These New, Cheaper Insulins

This legislation aims to help you and your doctor understand the potential benefits of cost-saving biosimiliar drugs and how to access them.

Insulin Prices Are Rising Unchecked. New Biosimilar Insulins May Cost You Less.

You may soon be able to substitute newer, cheaper insulins that work exactly the same as your current prescription.

Interchangeable Insulin: Here’s What You Need to Know

You may soon be able to substitute newer, cheaper insulins that work exactly the same as your current prescription.

What is Biosimilar Insulin?

The launch of biosimilar insulins will expand options for people with diabetes and may drive competition amid soaring prices at the pharmacy.

The Future of Insulin—Will It Be Affordable for the People Who Need It?

Research is showing promising advancements with new weekly oral and injectable insulins—but will they actually be affordable?

Access to Insulin: In the United States

Despite the growing variety of insulin and technology, access to this life-saving drug continues to be a dire problem in the United States.

Another Reminder that Racial/Ethnic Inequality Exists in Diabetes Care

Despite the variety of diabetes medications and technology, race and ethnicity still weigh heavily on a person’s access to these life-saving tools.

Access to Insulin: In Low-Income Countries

In many countries, a person with diabetes may walk for four days to get a vial of short-acting insulin and seven to 10 days for long-acting.